文献速递结核与非结核分枝杆菌

更高利福平剂量缩短治疗疗程的潜力:肺结核患者药物暴露与治疗反应的关系

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.
PubMed 文献 · Clin Infect Dis · 2018-01-01

该分析基于336例肺结核患者(其中97例有药代动力学数据),利福平剂量为10、20或35 mg/kg,采用参数化时间-事件方法分析利福平血浆暴露与6个月内治疗反应的关系。结果显示,利福平暴露越高,早期培养转阴概率越高,且效应未达平台;当利福平曲线下面积从20增至175 mg/L·h(分别代表10和35 mg/kg)时,第8周液体培养基稳定培养转阴的预期比例从39%(95%CI 37%-41%)升至55%(95%CI 49%-61%)。结论认为增加利福平暴露可缩短至稳定培养转阴时间,且效应未饱和,提示>35 mg/kg的剂量可能更有效。

要点

  • 利福平暴露越高,早期痰培养转阴概率越高,观察范围内未检测到效应上限。
  • 利福平曲线下面积从20增至175 mg/L·h(代表10和35 mg/kg)时,第8周液体培养基稳定培养转阴预期比例从39%升至55%。
  • 至稳定培养转阴的其他预测因素包括基线细菌载量、培养结果不可用比例以及用乙胺丁醇替代莫西沙星或SQ109。

核心结论

  • 增加利福平暴露可缩短至稳定培养转阴时间,且效应未达平台,提示>35 mg/kg的剂量可能更有效。
  • 优化利福平剂量同时预防毒性是临床优先事项。

研究设计与样本

  • 分析来自一项研究中的336例肺结核患者(其中97例有药代动力学数据),利福平剂量为10、20或35 mg/kg。
  • 反应指标为至稳定痰培养转阴时间(TSCC),采用先前建立的利福平群体药代动力学模型推导个体暴露指标。
  • TSCC采用参数化时间-事件方法建模,并进行序贯暴露-反应分析。

主要发现

  • 利福平暴露越高,早期培养转阴概率越高,观察范围内未检测到效应上限。
  • 当利福平曲线下面积从20增至175 mg/L·h(分别代表10和35 mg/kg)时,第8周液体培养基稳定培养转阴的预期比例从39%(95%CI 37%-41%)升至55%(95%CI 49%-61%)。
  • 至稳定培养转阴的其他预测因素包括基线细菌载量、培养结果不可用比例以及用乙胺丁醇替代莫西沙星或SQ109。

关键数值与推荐

  • 利福平曲线下面积20 mg/L·h(代表10 mg/kg)时,第8周液体培养基稳定培养转阴预期比例为39%(95%CI 37%-41%)。
  • 利福平曲线下面积175 mg/L·h(代表35 mg/kg)时,第8周液体培养基稳定培养转阴预期比例为55%(95%CI 49%-61%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tuberculosis remains a huge public health problem and the prolonged treatment duration obstructs effective tuberculosis control. Higher rifampicin doses have been associated with better bactericidal activity, but optimal dosing is uncertain. This analysis aimed to characterize the relationship between rifampicin plasma exposure and treatment response over 6 months in a recent study investigating the potential for treatment shortening with high-dose rifampicin. METHODS: Data were analyzed from 336 patients with pulmonary tuberculosis (97 with pharmacokinetic data) treated with rifampicin doses of 10, 20, or 35 mg/kg. The response measure was time to stable sputum culture conversion (TSCC). We derived individual exposure metrics with a previously developed population pharmacokinetic model of rifampicin. TSCC was modeled using a parametric time-to-event approach, and a sequential exposure-response analysis was performed. RESULTS: Higher rifampicin exposures increased the probability of early culture conversion. No maximal limit of the effect was detected within the observed range. The expected proportion of patients with stable culture conversion on liquid medium at week 8 was predicted to increase from 39% (95% confidence interval, 37%-41%) to 55% (49%-61%), with the rifampicin area under the curve increasing from 20 to 175 mg/L·h (representative for 10 and 35 mg/kg, respectively). Other predictors of TSCC were baseline bacterial load, proportion of culture results unavailable, and substitution of ethambutol for either moxifloxacin or SQ109. CONCLUSIONS: Increasing rifampicin exposure shortened TSCC, and the effect did not plateau, indicating that doses >35 mg/kg could be yet more effective. Optimizing rifampicin dosage while preventing toxicity is a clinical priority.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Svensson EM, Svensson RJ, Te Brake LHM, et al. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clin Infect Dis. 2018. PMID: 29917079. doi:10.1093/cid/ciy026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。